Limited Cutaneous Leishmaniasis as Ulcerated Verrucous Plaque on Leg, Tucson, Arizona, USA

We report a 34-year-old man who had a nonhealing, verrucous plaque with central ulceration on the lower leg. This case-patient is a rare example of endemic limited cutaneous leishmaniasis in Tucson, Arizona, USA. Clinicians should be aware of this disease because its manifestations can vary for individual patients.

with the understanding that this information mighty be publicly available.
The patient had no major medical history and no history of skin cancer or immunosuppression. He came to the dermatology clinic in Tucson, Arizona, because of a new onset of a painless lesion on the right lateral lower leg. The lesion was present for 6 weeks before the visit. Physical examination demonstrated a 2.1 × 1.1 cm solitary, nonhealing, verrucous plaque with central ulceration on the right proximal lateral pretibial region (Figure). The patient reported considerable time outdoors and recreational activities, such as mountain biking and hiking. Those activities occurred in Arizona; he specifically denied a history of recent travel outside of the United States. He also denied any trauma to the site of infection.
Shave biopsy and subsequent staining with hematoxylin and eosin showed focal ulceration with mixed acute, chronic, and granulomatous inflammatory infiltrate and minute organisms in the cytoplasm of histocytes favoring parasitized histiocytic infection. The organisms were negative by staining with periodic acid-Schiff. Microscopic examination was then completed by the Centers for Disease Control and Prevention, and small intracellular organisms compatible with protozoal amastigotes were observed within macrophages. Immunohistochemical analysis subsequently confirmed a diagnosis of leishmaniasis. The patient was referred to an infectious disease department, where observation was recommended because he had a solitary cutaneous lesion that was removed in entirety by biopsy. He also had no mucosal involvement.
In this case, the new-onset ulcerated plaque was initially most concerning for infectious versus neoplastic etiology. Although an infectious process was considered, CL was not on the original differential diagnosis given the rarity of this diagnosis in Arizona. This case helps demonstrate that leishmaniasis must be a consideration when patients in Arizona have verrucous papules or plaques.
Most autochthonous cases of CL in the Unites States have been in Texas (6). In 2018, a study in Texas identified 69 novel cases of leishmaniasis and 22 having documented speciation (all L. mexicanca) (4). CL is probably underreported because reporting is not required in most states, and a high rate of misdiagnosis can be presumed (4,6). Sand flies capable of transmitting L. mexicana have been reported in several states (7).
CL treatment decreases the risk for mucosal dissemination, accelerates healing of the lesion, decreases the risk for relapse, and decreases illness. Relapse We report a 34-year-old man who had a nonhealing, verrucous plaque with central ulceration on the lower leg. This case-patient is a rare example of endemic limited cutaneous leishmaniasis in Tucson, Arizona, USA. Clinicians should be aware of this disease because its manifestations can vary for individual patients.
of cutaneous disease (leishmaniasis recidivans) can occur several years after resolution of the primary lesion in treated and untreated patients (9). Treatment options for CL include systemic miltefosine (for Leishmania [Viannia] spp.), ketoconazole (for L. mexicana), and fluconazole or local therapy (antimonial drugs, topical paromomycin, or liquid nitrogen therapy) (9).
Treatment of leishmaniasis is determined by species, risk for mucosal dissemination, size, number, and location of lesion(s). Limited CL does not require further treatment if the findings self-resolve. CL can spontaneously resolve within 2 months to a year. CL that has >5 lesions; an area >5 cm; is on the face, toes, fingers, or genitalia; or has a duration >6 months might require treatment to prevent relapse or progression to mucosal disease (2). Other complications of CL include secondary infections and scarring (8).
CL treatment decreases the risk for mucosal dissemination, accelerates healing of the lesion, decreases the risk for relapse, and decreases illness. Relapse of cutaneous disease (leishmaniasis recidivans) can occur several years after resolution of the primary lesion in treated and untreated patients (9). Treatment options for CL include systemic miltefosine (for Leishmania [Viannia] spp.), ketoconazole (for L. mexicana), and fluconazole or local therapy (antimonial drugs, topical paromomycin, or liquid nitrogen therapy) (9).
In conclusion, CL is an increasing concern in the United States where endemic cases have been identified, most prominently the southern and southwestern regions. Our case adds to the short but increasing list of documented CL cases in Arizona. Placing CL in the differential diagnosis for new-onset verrucous plaques of unknown etiology in local disease-endemic areas of the United States is prudent. Limited CL can be managed conservatively with monitoring for recurrence once the solitary lesion has been removed, but further treatment might be necessary depending on the manifestations in an individual patient.